Login
$RNA
$6.52 +$0.09 (1.4%) After hours

$RNA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome —

02 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.2 Atrium Therapeutics 2 November 2026 RNA L I S T E D www.atriumtherapeutics.com NASDAQ 1

27 Oct 2026 8-K: Other Events

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

09 Oct 2026 8-K/A: Other Events

As previously disclosed in the Original Form 8-K, on October 7, 2026, the Company entered into a securities purchase agreement with selected investors that qualify as “accredited investors” (collectively, the “PIPE Investors”), as define...

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and among Atrium Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement...

22 Sep 2026 Form 4: Younis Husam, Chief Scientific Officer

Gave up 11,216 shares to cover exercise price or tax ($100K)

22 Sep 2026 Form 4: Hughes Steven George, Chief Medical Officer

Gave up 21,459 shares to cover exercise price or tax ($192K)

22 Sep 2026 Form 4: Flanagan W. Michael, Director

Gave up 22,812 shares to cover exercise price or tax ($204K)

22 Sep 2026 Form 4: Boyce Sarah, Director

Gave up 126,418 shares to cover exercise price or tax ($1.13M)

22 Sep 2026 Form 4: Kenney Stephanie, See Remarks

Gave up 2,375 shares to cover exercise price or tax ($21.3K)

22 Sep 2026 Form 4: Gallagher Kathleen P., Director

Gave up 11,632 shares to cover exercise price or tax ($104K)

22 Sep 2026 Form 4: Winslow Brendan R., Chief Financial Officer

Gave up 6,742 shares to cover exercise price or tax ($60.3K)

22 Sep 2026 Form 4: Hoyos Rocio Martin, Chief Strategy Officer

Gave up 8,320 shares to cover exercise price or tax ($74.5K)

14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

— IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support